neisseria lactamica

Cell therapyexperimental

Neisseria lactamica is a gram-negative diplococcus bacterium. It is strictly a commensal species of the nasopharynx. Uniquely among the Neisseria they are able to produce β-D-galactosidase and ferment lactose. — Wikipedia

Clinical trial activity

7 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2013 (NCT02249598)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • neisseria lactamica

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04784845N/AOct 1, 2021Moorgreen Hospital, Southampton, University of Edinburgh
NCT04665791N/AMar 2, 2021Center for Vaccine Development CVD-Mali, Moorgreen Hospital, Southampton, Public Health England, University of London, University of Maryland, University of Oxford
NCT04135053N/AFeb 1, 2019Moorgreen Hospital, Southampton
NCT03633474Early Phase 1 (Phase 1)Sep 1, 2018Moorgreen Hospital, Southampton
NCT03630250Early Phase 1 (Phase 1)Sep 1, 2018Moorgreen Hospital, Southampton
NCT03549325N/AFeb 15, 2017Moorgreen Hospital, Southampton
NCT02249598N/AJul 1, 2013Sheffield Hallam University
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Moorgreen Hospital, SouthamptonAcademic/Hospital6522017
Center for Vaccine Development CVD-MaliAcademic/Hospital1112021
Public Health EnglandGovernment1012021
Sheffield Hallam UniversityAcademic/Hospital1112013
University of EdinburghAcademic/Hospital1012021
University of LondonAcademic/Hospital1012021
University of MarylandAcademic/Hospital1012021
University of OxfordAcademic/Hospital1012021
8 organizations
Page 1 / 1